we conclude that although both oral and transdermal oestradiol reduce postmenopausal bone loss , gonadotrophin secretion and symptoms , oral treatment also leads to hepatic stimulation and extensive metabolism of oestradiol , both of which may increase side-effects without conferring additional benefit .
C0029458
postmenopausal bone loss
C0014912
oestradiol